Gold prices rise from 2-wk low with focus on Russia-Ukraine, Jackson Hole
Jacob Van Naarden, Executive Vice President and President of Lilly Oncology at Eli Lilly & Co (NYSE:LLY), acquired 1,000 shares of common stock on August 13, 2025, at a price of $647.36, in one transaction valued at $647,360.
Following the transaction, Van Naarden directly owns 20,561.985 shares of Eli Lilly & Co. He also indirectly owns 4,342 shares through the Van Naarden Family Trust and 4,302 shares by spouse.
In other recent news, Eli Lilly reported second-quarter 2025 earnings that surpassed expectations, both in terms of revenue and earnings per share, prompting the company to raise its full-year guidance. Despite these strong financial results, investor sentiment was impacted by disappointing clinical trial data for Eli Lilly’s weight loss drug candidate, Orforglipron. Cantor Fitzgerald responded by lowering its price target for Eli Lilly to $825 while maintaining an Overweight rating, citing concerns about Orforglipron’s performance relative to market expectations. Similarly, Guggenheim reduced its price target to $875, maintaining a Buy rating, as attention shifted to the clinical trial results of the drug. Meanwhile, JPMorgan reiterated its Overweight rating with a price target of $1,100, maintaining a positive outlook despite the clinical trial concerns. In legal developments, Eli Lilly faces a lawsuit filed by the Texas Attorney General, accusing the company of bribing healthcare providers to prescribe its medications, specifically mentioning GLP-1 drugs Mounjaro and Zepbound. These recent developments are significant for investors monitoring Eli Lilly’s performance and future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.